This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bailey, C. J Articles by Day, C. Search for Related Content Social Bookmarking                         What's this?

Increasing choice to treat obesity

Diabetes Research Group, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK, c.j.bailey{at}aston.ac.uk

Caroline Day

Diabetes Research Group, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK

References

• Bray GA Risks of obesity. Endocrinol Metab Clin N Am 2003;32:787-804.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Williams KV, Kelley DE Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000;2:121-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Norris SL, Zhang X., Avenell A. et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. A meta-analysis. Arch Intern Med 2004;164:1395-404.[Abstract/Free Full Text]
• Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Despres JP, Golay A., Sjostrom L. et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.[Abstract/Free Full Text]
• Scheen AJ Rimonabant in overweight and obese type 2 diabetes. American Diabetes Association. 65th annual Scientific Sessions: Abstract 7-LB. Presented 12 June 2005.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3, 101 (2006)
DOI: 10.1177/14746514060060030101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bailey, C. J Articles by Day, C. Search for Related Content Social Bookmarking                         What's this?